Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $122B | $130B | $137B | $146B | $153B | $162B | $181B | $205B | $227B | $223B |
| Revenue growth | — | 6.9% | 5.3% | 6.4% | 5.1% | 6.2% | 11.6% | 13.0% | 10.7% | -1.9% |
| Gross profit | $6.54B | $6.54B | $7.18B | $6.83B | $6.87B | $6.78B | $6.48B | $6.87B | $7.41B | $8.17B |
| Gross margin | 5.4% | 5.0% | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% |
| Operating income | $2.46B | $2.12B | $126M | $2.06B | -$4.10B | $472M | -$607M | $752M | $1.24B | $2.27B |
| Operating margin | 2.0% | 1.6% | 0.1% | 1.4% | -2.7% | 0.3% | -0.3% | 0.4% | 0.5% | 1.0% |
| Net income | $1.43B | $1.29B | $256M | $1.36B | -$3.70B | $611M | -$938M | $330M | $852M | $1.56B |
| Net margin | 1.2% | 1.0% | 0.2% | 0.9% | -2.4% | 0.4% | -0.5% | 0.2% | 0.4% | 0.7% |
| EPS (diluted) | $4.32 | $4.03 | $0.81 | $4.53 | -$12.61 | $2.08 | -$3.37 | $1.26 | $3.45 | $6.45 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.97B | $1.18B | $2.77B | $2.72B | $1.96B | $2.43B | $3.17B | $2.84B | $3.76B | $2.40B |
| Capital expenditures | $465M | $387M | $384M | $328M | $375M | $400M | $387M | $481M | $511M | $547M |
| Free cash flow | $2.51B | $797M | $2.38B | $2.39B | $1.58B | $2.03B | $2.79B | $2.36B | $3.25B | $1.85B |
| Share buybacks | $651M | $600M | $550M | $600M | $350M | $200M | $1.00B | $2.00B | $750M | $765M |
| Dividends paid | $512M | $577M | $581M | $577M | $569M | $573M | $559M | $525M | $499M | $494M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.36B | $6.88B | $1.76B | $2.53B | $2.77B | $3.41B | $4.72B | $4.08B | $5.13B | $3.87B |
| Total assets | $34.1B | $40.1B | $40.0B | $41.0B | $40.8B | $44.5B | $43.9B | $43.3B | $45.1B | $53.1B |
| Shareholders' equity | $6.55B | $6.81B | $6.06B | $6.33B | $1.79B | $1.79B | -$709M | -$2.96B | -$3.21B | -$2.78B |
| Retained earnings | $6.42B | $4.97B | $4.64B | $5.43B | $1.17B | $1.21B | -$280M | -$642M | -$286M | $783M |
| Shares (wtd avg diluted) | 330M | 320M | 315M | 301M | 293M | 294M | 279M | 262M | 247M | 242M |
Every figure is extracted from CARDINAL HEALTH INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.